Journal: Journal of Advanced Research
Article Title: Andrographolide alleviates type 2 diabetic nephropathy through suppressing PI3K/AKT1/RRM2-triggered oxeiptosis
doi: 10.1016/j.jare.2025.10.070
Figure Lengend Snippet: Andrographolide (AND) inhibits hyperglycemia-induced oxeiptosis through dual suppression of PI3K/AKT1 and RRM2 and demonstrates enhanced potential for ameliorating type 2 diabetic nephropathy (T2DN) in combination with metformin (MET). (A) Effects of AND combined with AKT1 overexpression on the PI3K/AKT1 pathway, RRM2 expression, and oxeiptosis-associated proteins under 50 mM glucose (GLU) treatment. (B) Quantitative analysis of PI3K/AKT1 pathway activity, RRM2 expression, and oxeiptosis-related protein levels from (A). (C) Effects of AND combined with si-AKT1 on the PI3K/AKT1 pathway, RRM2 expression, and oxeiptosis markers under 50 mM GLU. (D) Quantitative analysis of PI3K/AKT1 pathway activity, RRM2 expression, and oxeiptosis-related protein levels from (C). (E) Apoptosis detection via Annexin V-mCherry/SYTOX Green staining in cells treated with AND combined with AKT1 overexpression or si-AKT1 under 50 mM GLU. Scale bar: 10 µM. (F) Quantitative analysis of Annexin V-mCherry-positive expression from (E). (G) Effects of AND combined with AKT1 overexpression or si-AKT1 on AIFM1 (pS116) expression and mitochondrial co-localization under 50 mM GLU. Scale bar: 10 µM. (H) Quantitative analysis of AIFM1 (pS116) levels from (G). (I) Effects of AND combined with RRM2 overexpression or si-RRM2 on the PI3K/AKT1 pathway, RRM2 expression, and oxeiptosis markers under 50 mM GLU. (J) Quantitative analysis of PI3K/AKT1 pathway activity, RRM2 expression, and oxeiptosis-related protein levels from (I). (K) Apoptosis detection via Annexin V-mCherry/SYTOX Green staining in cells treated with AND combined with RRM2 overexpression or si-RRM2 under 50 mM GLU. Scale bar: 10 µM. (L) Quantitative analysis of Annexin V-mCherry-positive expression from (K). (M) Effects of AND combined with RRM2 overexpression or si-RRM2 on AIFM1 (pS116) expression and mitochondrial co-localization under 50 mM GLU. Scale bar: 10 µM. (N) Quantitative analysis of AIFM1 (pS116) levels from (M). (O) Schematic diagram illustrating the mechanism by which AND suppresses high glucose-induced oxeiptosis through dual inhibition of PI3K/AKT1 and RRM2. The AND + MET combination provided superior improvement in HOMA-IR (P) and fasting blood glucose levels (Q) compared to MET alone. (R) Representative images of kidney sections subjected to H&E staining (Scale bar: 50 µm; blue arrows indicate cellular vacuolization, green arrows indicate proteinaceous mucus, purple arrows indicate mesangial expansion), MASSON staining (Scale bar: 100 µm; black arrows indicate collagen fiber deposition), PAS staining (Scale bar: 50 µm; blue arrows indicate glycogen deposition), and PASM staining (Scale bar: 50 µm; blue arrows indicate glomerular basement membrane thickening). (S) Effect of the AND + MET combination on the oxeiptosis-related protein expression in renal tissues. (T) Relative quantification of oxeiptosis-related protein levels from (S). (U) Effect of the AND + MET combination on the oxeiptosis-relate protein expression in MDCK cells treated with 50 mM GLU. (V) Relative quantification of oxeiptosis-related protein levels from (U). (W) Apoptosis detection via Annexin V-mCherry/SYTOX Green staining in cells treated with AND combined with MET under 50 mM GLU. Scale bar: 10 µM. (X) Quantitative analysis of Annexin V-mCherry-positive expression from (W). (Y) Effects of AND combined with MET on AIFM1 (pS116) expression and mitochondrial co-localization under 50 mM GLU. Scale bar: 10 µM. (Z) Quantitative analysis of AIFM1 (pS116) levels from (Y). All data are presented as mean ± SD, n = 3. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Article Snippet: To activate or inhibit the PI3K/AKT1 signaling pathway, MDCK cells were treated with Recilisib (HY-101625, MCE, China) or Miltefosine (HY-13685, MCE, China), respectively.
Techniques: Over Expression, Expressing, Activity Assay, Staining, Inhibition, Membrane, Quantitative Proteomics
ATCC is a verified supplier 
ATCC manufactures this product 
